| Keith Allen Beaulieu, MD | |
|
540 N Duke St, Suite 244, Lancaster, PA 17602-2374 | |
| (717) 544-4930 | |
| (717) 544-4964 |
| Full Name | Keith Allen Beaulieu |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 21 Years |
| Location | 540 N Duke St, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043474364 | NPI | - | NPPES |
| 1023706850001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MT182532 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pulmonary Associates Of Lancaster, Ltd | 7113903998 | 23 |
News Archive
Talking therapies for mental health conditions are among countless medical interventions that have been disrupted due to the Covid-19 pandemic.
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
› Verified 9 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1154331775 PECOS PAC ID: 1254240039 Enrollment ID: O20040414000520 |
News Archive
Talking therapies for mental health conditions are among countless medical interventions that have been disrupted due to the Covid-19 pandemic.
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
› Verified 9 days ago
| Entity Name | Pulmonary Associates Of Lancaster, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508818907 PECOS PAC ID: 7113903998 Enrollment ID: O20040624001076 |
News Archive
Talking therapies for mental health conditions are among countless medical interventions that have been disrupted due to the Covid-19 pandemic.
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
› Verified 9 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1730323759 PECOS PAC ID: 1254240039 Enrollment ID: O20090710000234 |
News Archive
Talking therapies for mental health conditions are among countless medical interventions that have been disrupted due to the Covid-19 pandemic.
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keith Allen Beaulieu, MD 540 N Duke St, Suite 244, Lancaster, PA 17602-2374 Ph: (717) 544-4930 | Keith Allen Beaulieu, MD 540 N Duke St, Suite 244, Lancaster, PA 17602-2374 Ph: (717) 544-4930 |
News Archive
Talking therapies for mental health conditions are among countless medical interventions that have been disrupted due to the Covid-19 pandemic.
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
› Verified 9 days ago
Kaci Elizabeth Christian, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2112 Harrisburg Pike Ste 202, Lancaster, PA 17601 Phone: 717-869-4600 Fax: 717-544-3501 | |
Nancy L Adamopoulos, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-8144 | |
Mark H Johnston, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2112 Harrisburg Pike, Suite 202, Lancaster, PA 17601 Phone: 717-544-3500 Fax: 717-544-3501 | |
John B Fileta, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1254 Lititz Pike, Lancaster, PA 17601 Phone: 717-397-4724 | |
Charles R Rost, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2112 Harrisburg Pike, Suite 200, Lancaster, PA 17601 Phone: 717-544-3059 Fax: 717-544-3638 | |
Dr. Paul David Allegretti, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2112 Harrisburg Pike, Suite 202, Lancaster, PA 17601 Phone: 717-544-3500 Fax: 717-544-3501 | |
Elyse Goveia, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-4940 |